Bioinformatics Analysis Identifies TNFRSF1A as a Biomarker of Liver Injury in Sepsis

Shangxun Zhou, Wei Zhao, Junjie Li, Yang Huang, Jing Yang, Qianmei Wang, Yunyun Xu, Chujun Duan, Yutong Wang, and Wen Yin

Department of Emergency, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shaanxi, China

Correspondence should be addressed to Yutong Wang; wangyutong@fmmu.edu.cn and Wen Yin; xjyyyw@126.com

Received 23 May 2022; Revised 26 September 2022; Accepted 29 September 2022; Published 15 October 2022

Copyright © 2022 Shangxun Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sepsis is a severe disease with high mortality, and liver injury is an independent risk factor for sepsis morbidity and mortality. We analyzed co-differentially expressed genes (co-DEGs) to explore potential biomarkers and therapeutic targets for sepsis-related liver injury. Three gene expression datasets (GSE60088, GSE23767, and GSE71530) were downloaded from the Gene Expression Omnibus (GEO). DEGs were screened between sepsis and control samples using GEO2R. The association of these DEGs with infection and liver disease was analyzed by using the CTD database. GO functional analysis, KEGG pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed to elucidate the potential molecular mechanism of DEGs. DEGs of different tissues in GSE60088 were analyzed again to obtain specific markers of septic liver injury. Mouse model of sepsis was also established by cecal ligation and puncture (CLP), and the expression of specific markers in liver, lung, and kidney tissues was analyzed using Western blot. Here, we identified 21 DEGs in three datasets with 8 hub genes, all of which showed higher inference scores in liver diseases than bacterial infections. Among them, only TNFRSF1A had a liver-specific differential expression. TNFRSF1A was also confirmed to be specifically reduced in septic liver tissues in mice. Therefore, TNFRSF1A may serve as a potential biomarker for septic liver injury.

1. Introduction

Sepsis is an infection-induced systemic inflammatory response syndrome. It is a common complication of patients with severe trauma, shock, and critical diseases and a leading cause of death for patients in the intensive care unit (ICU). The occurrence of sepsis is associated with the hypersensitivity cascade and excessive inflammatory mediators [1–3]. Identification of sepsis-related biomarkers is critical for the diagnosis to distinguish the severity and develop a treating strategy of sepsis. Increasing evidence has demonstrated that multiple genes are involved in sepsis progression and organ damage [4–7]. Zheng et al. identified fourteen long non-coding RNAs that could be used to diagnose sepsis patients with insignificant clinical manifestations [8]. Studies uncovered that the ribosome-related genes TLCD4, PRSS30P, and ZNF493 had a moderate performance to identify sepsis-induced acute respiratory distress syndrome (ARDS) in sepsis patients [9, 10]. Five genes (NKG7, SPTA1, FGL2, RGS2, and IFI27) have been proved to be potential biomarkers for sepsis-induced ARDS and exert crucial roles in the occurrence and development of sepsis [11]. Sepsis may also induce acute kidney injury (AKI), and studies showed that VMP1, SLPI, PTX3, TIMP1, OLFM4, LCN2, and S100A9 genes were markedly correlated with the development and progression of septic-shock-associated AKI [12]. Sepsis-caused failure in different tissues has different mechanisms. Serving as an important host defense organ through bacterial clearance, acute phase proteins, cytokine generation, and metabolic adaptation to inflammation, the
liver is one of the most vulnerable organs in patients with sepsis. Sepsis-induced liver injury or dysfunction is considered as a strong independent predictor of mortality in ICU (up to 54-68%) [13–15]. However, the genes involved in sepsis-induced liver injury remain unclear.

Microarray technology and bioinformatics analysis have been widely used to screen for genetic alterations at the genome level, contributing to the identification of differentially expressed genes (DEGs) and functional pathways in disease models. Analysis of microarray data in a septic liver injury model can build gene networks and screen for potential key molecular targets to provide a new understanding of the pathogenesis of septic liver injury and a potential strategy for clinical treatment [16, 17]. In this study, we downloaded and analyzed three mRNA microarray datasets from the Gene Expression Omnibus (GEO) database to obtain DEGs between normal and septic liver tissues. The GO functional analysis, KEGG pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed, and a total of 21 DEGs and 8 hub genes were identified, of which only TNFRSF1A was critical for the specificity of septic liver injury, which could be a candidate biomarker.

2. Methods

2.1. Microarray Data. GEO (https://www.ncbi.nlm.nih.gov/geo) is a public functional genomics repository containing global gene expression data and microarrays [18]. Three gene expression datasets, GSE60088 [19], GSE23767 [20], and GSE71530 [21], were downloaded from public GEO (Affymetrix GPL570 platform, Affymetrix Human Genome U133 Plus 2.0). Among them, GSE60088 contains 5 sepsis samples and 3 control samples; GSE23767 includes 4 sepsis and 3 control samples; and GSE71530 contains 3 sepsis and 3 control samples. The datasets from septic and normal liver tissues were collected and screened for subsequent analysis.

2.2. Identification of DEGs. GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r) was used to screen significant DEGs between sepsis and control liver samples. The application of P-values and Benjamini and Hochberg false discovery rates provided a balance between the discovery of statistically significant genes and false positive limits. The probe sets without any gene symbols or genes with multiple probe sets were excluded or averaged, respectively. A fold change (logFC) >1 and P-value <0.05 were considered statistically significant.

2.3. PPI Network Construction and Analysis. PPI networks were predicted using an online database searching tool (STRING; https://www.string-db.org) to retrieve gene interactions [22]. Analysis of protein functional interactions provides insights into the inner mechanism of the related disease pathogenesis and development. In this study, the PPI network of DEGs was constructed by using the STRING, and interactions with a combined score >0.4 were considered to have statistical significance. Cytoscape software was applied to construct and visualize the molecular interaction network.

2.4. KEGG and GO Enrichment Analyses of DEGs. The Database for Annotation, Visualization, and Integrated Discovery 6.7 (DAVID; https://www.david.ncifcrf.gov) is an online bioinformatics database that integrates biological data and analysis tools to provide complete annotation information of functional genes and proteins for users [23]. GO functional analysis (including cellular composition [CC], biological process [BP], and molecular function [MF]) is a major bioinformatics tool that can classify gene expression and its related biological processes [24]. KEGG is a database resource that integrates large-scale molecular datasets using high-throughput techniques to understand their related functional pathways and biological systems [25]. To analyze the functions of screened DEGs, DAVID and the online bioinformatics database were used to perform biological analyses. P < 0.05 was considered statistically significant.

2.5. Associations of Common DEGs with Infection and Liver Disease. The Comparative Toxicogenomics Database (CTD; https://www.ctdbase.org/) is a public resource that describes the interactions between environmental chemicals and gene products and their relationship to disease [26]. We used these data to analyze and determine the association of common DEGs with infection and liver disease.

2.6. Mouse and Histological Analysis (Experimental Study). Male C57BL/6 mice (6-8-week-old, weighing 20-25 g) from the Fourth Military Medical University (Xi’an, China) were housed under standard laboratory conditions. Mice were randomly divided into sham (n = 3) and CLP (n = 3) groups. The sepsis model was induced by CLP as previously described [27]. The experiment was repeated three times. Mice in the sham group were administrated with similar procedures without CLP. All mice were received 1 mL of normal saline in the abdominal cavity after surgery to compensate for fluid loss. While animals subjected to CLP appear healthy in the initial phase after the procedure, they begin to show clinical signs of sepsis at around 12h following CLP, featuring malaise, fever, chills, piloerection, generalized weakness, and reduced gross motor activity. After 24 hours, the mice were sacrificed by decapitation, and the liver, lung, and kidney specimens were collected for hematoxylin and eosin (HE) staining. Briefly, the tissues were paraffin-embedded, sectioned at 5 μm thickness, and stained with hematoxylin and eosin. The pathological sections were randomly observed by pathologists to analyze the pathological damage in each group. The animal study was performed following the Guide for the Care and Use of Laboratory Animals and approved by the ethics committee of the Xijing Hospital (approval number KY20193106).

2.7. Western Blot. Total proteins of the liver, lung, and kidney tissue samples from normal and septic mice were extracted using RIPA buffer (containing 1% PMSF and 1%
protease inhibitors). BCA protein assay kit (Pierce, Rockford, USA) was used for protein quantification. Certain amounts of protein were loaded onto the SDS-PAGE gels and then transferred to PVDF membranes for Western blot analysis. After blocking, the membranes were incubated with the anti-TNFRSF1A primary antibody at 4°C overnight, followed by incubation with diluted HRP-conjugated secondary antibody (Pierce Biotechnology, Inc, Rockford, IL, USA) for 1 h at room temperature. Blots were visualized with ECL-Plus reagent (GE Healthcare, Piscataway, NJ). β-Actin antibody was used to confirm equal protein loading.

2.8. Statistical Analysis. Data analysis was performed using GraphPad Prism software (v.6.0; GraphPad software, La Jolla, CA, USA). Student’s t-test was used. All animal experiments had at least three replicates. A value of $P < 0.05$ was considered statistically significant.

3. Results

3.1. Identification of DEGs in Septic Liver Tissue. After normalization of the microarray results, there were 364, 1,030, and 665 DEGs identified in GSE60088, GSE23767, and GSE71530, respectively (Figure 1(a)). The overlap between the 3 datasets contained 21 genes, in which 15 genes were downregulated and 6 were upregulated in sepsis compared with the control (Figure 1(b)). A PPI network was constructed to show the interaction between these 21 genes (Figure 1(c)). Among them, eight of the 21 genes were closely interacted (Figure 1(c)), all of which were downregulated. Table 1 shows the brief description of them.

3.2. Functional Enrichment and Disease Association Analysis of DEGs. We further analyzed the functional and pathway enrichment of the eight DEGs through DAVID. Results from GO functional analysis indicated that the alteration of BP was mainly on the inflammatory and immune responses (Figure 2(a)). The changes of CC of DEGs focused largely on the membrane-related regions (Figure 2(b)), and MF alterations were mainly in the cytokine or chemical receptor binding (Figure 2(c)). KEGG pathway enrichment analysis showed that these DEGs were mainly involved in cytokine interaction, adipocytokine signaling, rheumatoid arthritis, toxoplasmosis, hepatitis C, JAK-STAT3 pathway, and chemokine signaling pathways (Figure 2(d)). The CTD database was applied to evaluate the association between the eight DEGs and infections and liver diseases. Results showed that all of them had greater inference scores associated with liver injury or disease than bacterial infections (Table 2).

3.3. Identification of TNFRSF1A as a liver-specific DEG in Sepsis. The eight DEGs were compared with the DEGs in the septic liver, kidney, and lung tissues of GSE60088, and it was found that only TNFRSF1A had a specific expression change in the liver (Table 3). Combined with the higher association of TNFRSF1A with liver-related diseases or injury than infections, it seemed that TNFRSF1A may be specific in liver disease. We further established CLP-induced sepsis mouse model. HE staining of the liver, lung, and kidney tissues of sham and CLP groups showed that all tissues were structurally disordered and had more or less inflammatory infiltration after CLP (Figure 3(a)). Liver tissues in sham were intact with normal and well-structured hepatic cells, while necrotic hepatocytes with extensive vacuolar degeneration and nuclear rupture were observed in the liver after CLP. The protein levels of TNFRSF1A in these animal septic tissues were detected through Western blot, which showed that TNFRSF1A was significantly downregulated in the liver tissues of septic mice compared with the sham. There was no big change between them in the lung and kidney (Figure 3(b)). Moreover, we searched TNFRSF1A in the KEGG database, which showed that TNFRSF1A, binding to TNF-α, mainly participates in the mTOR, MAPK, caspase 3, and NFκB pathways that were related to the regulation of inflammatory responses and cell apoptosis (Figure 4).

4. Discussion

Despite extensive research in sepsis, there are still few biomarkers that can be used to effectively detect and treat sepsis [28]. Liver has a regenerative function and capability to withstand attack. In sepsis, the liver is a major site occurring inflammatory responses to defend bacterial endotoxins. Once liver dysfunction or failure happens, the damaged liver may cause severe systemic inflammatory responses spreading to other organs, leading to complication progression and even death [29–31]. Hence, the identification of liver damage-related genes could provide new targets and strategies for exploring the effects of the liver in sepsis and its related treatments.

Microarray assay is an effective method to screen novel biomarkers of disease and find genetic alterations in disease progression, which has been proved to be applicable in the study of septic biomarkers and organ damage [32]. In the current study, three databases GSE60088, GSE23767, and GSE71530 were found by screening the experimental data of sepsis complicated with liver injury in the GEO database. We applied microarray assay analysis and obtained 21 DEGs between septic liver tissues and normal ones, including 15 downregulated (ST5, NFKBIZ, PDK4, OSMR, STAT3, CPNE8, S100A9, TNFRSF1A, ICAM1, SLC39A14, SLC41A2, FGL1, CXCL1, LITAF, and SAA2) and 6 upregulated genes (HES6, STBD1, DEXI, PANK1, SLC46A3, and NUDT17). Among them, only 8 downregulated genes (OSMR, TNFRSF1A, ICAM1, STAT3, CXCL1, NFKBIZ, LITAF, and SAA2) interacted through the proteins they expressed. To analyze the association of these 8 key genes with sepsis and liver injury, we performed GO functional analysis and KEGG pathway enrichment analysis on them; GO functional analysis showed that they were mainly involved in the processes of acute inflammatory response, positive regulation of inflammatory response, activation of T cells in the immune response, and positive regulation of defense response. KEGG pathway enrichment analysis showed that they were enriched in the pathways associated with cytokine interactions. It was worth noting that
Table 1: Description of the eight hub genes among the 21 overlapping genes in GSE60088, GSE23767, and GSE71530 datasets.

| No | Gene symbol | Full name                                                                 | Function                                                                 |
|----|-------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------|
| 1  | OSMR        | Oncostatin M receptor                                                     | Binds IL31 to activate STAT3 and possibly STAT1 and STAT5               |
| 2  | TNFRSF1A    | Tumor necrosis factor receptor superfamily, member 1a                    | Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha  |
| 3  | ICAM1       | Intercellular adhesion molecule 1                                         | ICAM proteins are ligands for the leukocyte adhesion protein LFA-1       |
| 4  | STAT3       | Signal transducer and activator of transcription 3                       | Transcription factor that binds to the IL-6 responsive elements          |
|    |             |                                                                           | identified in the promoters of various acute-phase protein genes        |
| 5  | CXCL1       | Chemokine (C-X-C motif) ligand 1                                          | Has chemotactic activity for neutrophils. Contributes to neutrophil      |
|    |             |                                                                           | activation during inflammation                                           |
| 6  | NFKBIZ      | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta | Inhibits NF-kappa-B activity without affecting its nuclear translocation |
|    |             |                                                                           | upon stimulation. It is recruited to IL-6 promoters and activates IL-6   |
|    |             |                                                                           | but decreases TNF-alpha production in response to LPS                    |
| 7  | LITAF       | LPS-induced TN factor                                                     | May regulate through NFKB1 the expression of the CCL2/MCP-1 chemokine   |
|    |             |                                                                           | May play a role in tumor necrosis factor alpha (TNF-alpha) gene expression|
| 8  | SAA2        | Serum amyloid A 2                                                         | Major acute phase reactant. Apolipoprotein of the HDL complex           |
TNFRSF1A, STAT3, ICAM1, and OSMR are involved in multiple biological processes and signaling pathways in each enrichment analysis. We speculated that the overlap in significantly enriched GO terms and KEGG pathway might represent vital pathways in the sepsis-induced liver injury. During sepsis, it is very likely that the liver plays a role in immune regulation and inflammatory clearance through one or more of these 4 key genes. Moreover, all these 8 genes showed higher correlation with liver diseases than bacterial infections in the CTD database.

However, these DEGs were not liver-specific. Through further analysis of dataset GSE60088 that contained DEGs of the septic liver, lung, and kidney, it was found that only TNFRSF1A was differentially liver-specific expressed among the 4 key genes. The effects of TNF-α can be exerted through two different receptors belonging to the TNF receptor superfamily. The type I receptor is TNFRSF1A, also known as p55, p60, CD120a, or TNFR1. TNFRSF1A is a 60 kDa transmembrane glycoprotein and expressed in almost all cells except for erythrocytes, but type II receptor mainly exists in immune cells, endothelial cells, and cells of the hematopoietic lineage. Both receptors can be activated by transmembrane TNF-α, but TNFRSF1A can also have functions by soluble TNF-α [33]. The activation of THFR induces the release of proinflammatory cytokines and chemokines. Other than that, TNFRSF1A possesses a cytoplasmic death domain (DD) that allows them to transduce regulated prodeath signals, leading to apoptosis or necrosis [34, 35]. Several studies have investigated and revealed the role of TNFR in the development of early and late renal failure, including diabetic nephropathy, renal angiosclerosis, acute renal transplant rejection, renal cell carcinoma,
glomerulonephritis, sepsis, and obstructive renal injury [36]. In addition, TNFRSF1A mutation-caused tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is the first and the only disease known to be caused by receptor structure mutation [37]. In sepsis, TNFRSF1A is a key participant during Staphylococcus aureus infections and is associated with the bacterial clearance from the spleen [38]. The significant increase of soluble TNFRSF1A in the circulation is closely related to sepsis. Using soluble TNFRSF1A to neutralize TNF reduces organ damage and mortality in sepsis rat [39].

In our experimental study, TNFRSF1A expression was detected in the liver, lung, and kidney tissues of sepsis mice, and only TNFRSF1A in the liver was significantly downregulated, which was consistent with the bioinformatics analysis. Hepatocytes from septic mice developed extensive vacuolar degeneration and nuclear rupture, which were closely related to the cytokine storm and inflammatory

| Gene   | Disease name                                | Disease ID      | Inference score | Reference count |
|--------|---------------------------------------------|-----------------|-----------------|-----------------|
| OSMR   | Bacterial infections                        | MESH: D001424   | 11.47           | 4               |
|        | Bacteremia                                  | MESH: D016470   | 6.67            | 5               |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 181.83          | 996             |
|        | Liver diseases                              | MESH: D008107   | 97.81           | 80              |
|        | Liver failure, acute                        | MESH: D017114   | 44.32           | 190             |
| TNFRSF1A | Bacterial infections                        | MESH: D001424   | 12.97           | 10              |
|        | Bacteremia                                  | MESH: D016470   | 7.65            | 7               |
|        | Staphylococcal infections                   | MESH: D013203   | 15.66           | 112             |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 373.55          | 1473            |
|        | Liver diseases                              | MESH: D008107   | 173.23          | 133             |
|        | Liver failure, acute                        | MESH: D017114   | 105.65          | 219             |
| ICAM1  | Bacterial infections                        | MESH: D001424   | 38.09           | 14              |
|        | Bacteremia                                  | MESH: D016470   | 10.32           | 8               |
|        | Immune suppression                          | OMIM: 146850    | 22.44           | 4               |
|        | Staphylococcal infections                   | MESH: D013203   | 31.17           | 123             |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 624.5           | 1763            |
|        | Liver diseases                              | MESH: D008107   | 253.83          | 168             |
|        | Liver failure, acute                        | MESH: D017114   | 145.9           | 251             |
| STAT3  | Bacterial infections                        | MESH: D001424   | 30.62           | 14              |
|        | Bacteremia                                  | MESH: D016470   | 9.5             | 4               |
|        | Immune suppression                          | OMIM: 146850    | 15.89           | 113             |
|        | Staphylococcal infections                   | MESH: D013203   | 27.98           | 126             |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 492.25          | 1599            |
|        | Liver diseases                              | MESH: D008107   | 194.1           | 160             |
|        | Liver failure, acute                        | MESH: D017114   | 119.02          | 220             |
| CXCL1  | Bacterial infections                        | MESH: D001424   | 38.75           | 13              |
|        | Bacteremia                                  | MESH: D016470   | 19.38           | 11              |
|        | Immune suppression                          | OMIM: 146850    | 27.98           | 126             |
|        | Staphylococcal infections                   | MESH: D013203   | 492.25          | 1599            |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 118.82          | 94              |
|        | Liver diseases                              | MESH: D008107   | 71.4            | 189             |
|        | Liver failure, acute                        | MESH: D017114   | 119.02          | 220             |
| NFBKIZ | Bacterial infections                        | MESH: D001424   | 20.71           | 10              |
|        | Pneumococcal infections                     | MESH: D011008   | 11.06           | 4               |
|        | Staphylococcal infections                   | MESH: D013203   | 13.23           | 110             |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 223.35          | 1151            |
|        | Liver diseases                              | MESH: D008107   | 118.82          | 94              |
|        | Liver failure, acute                        | MESH: D017114   | 71.4            | 189             |
| LITAF  | Bacterial infections                        | MESH: D001424   | 20.71           | 8               |
|        | Pneumococcal infections                     | MESH: D011008   | 11.09           | 4               |
|        | Staphylococcal infections                   | MESH: D013203   | 10.05           | 99              |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 269.74          | 1285            |
|        | Liver diseases                              | MESH: D008107   | 145.5           | 101             |
|        | Liver failure, acute                        | MESH: D017114   | 80.37           | 205             |
| SAA2   | Bacterial infections                        | MESH: D001424   | 5.71            | 2               |
|        | Candidiasis                                 | MESH: D002177   | 7.29            | 13              |
|        | Q fever                                     | MESH: D01778    | 9.64            | 1               |
|        | Chemical and drug-induced liver injury      | MESH: D056486   | 146.38          | 987             |
|        | Liver diseases                              | MESH: D008107   | 96.08           | 79              |
|        | Liver failure, acute                        | MESH: D017114   | 36.44           | 165             |
cascade triggered by sepsis. Membrane TNFRSF1A induces cellular inflammatory damage and apoptosis by participating in mTOR, JNK, IKK, caspase 3, MAPK, and NF-kB pathways. Therefore, the decreased TNFRSF1A protein expression in the liver tissue of the sepsis model combined with the downregulation of gene expression verified that TNFRSF1A may serve as a specific biomarker of septic liver damage and liver immunoregulation. Although the mortality of TNFRSF1A $^{-/-}$ mice in sepsis was comparable with wildtype mice [40], it is still undeniable the

---

**Table 3**: TNFRSF1A has a specific expression change (✓) in liver tissues after comparison with the DEGs in GSE60088.

| Gene symbol | Liver | Lung | Kidney |
|-------------|-------|------|--------|
| OSMR        | ✓     |      | ✓      |
| TNFRSF1A    | ✓     | ✓    |        |
| ICAM1       | ✓     | ✓    |        |
| STAT3       | ✓     | ✓    |        |
| CXCL1       | ✓     | ✓    |        |
| NFKBIZ      | ✓     | ✓    |        |
| LITAF       | ✓     | ✓    |        |
| SAA2        | ✓     | ✓    |        |

---

**Figure 3**: Identification of TNFRSF1A as a liver-specific DEG in sepsis. CLP-induced sepsis mouse model was established. (a) Representative HE staining images of the liver, lung, and kidney tissues of sham and CLP groups. Scale bar means 50 μm. (b) Relative expression of TNFRSF1A in these animal septic tissues was detected through Western blot. “∗∗” $P < 0.01$ vs. Sham group.
important role of TNFRSF1A in septic liver injury. The extracellular domain of membrane-bound TNFR1 can be proteolytic-cleaved. Deng et al. confirmed that TNFR1 shedding in hepatocytes is through the iNOS-cGMP-TACE pathway to defend bacterial lipopolysaccharide [41], so intervention of this pathway may be beneficial for the early clinical cause of severe sepsis. Nevertheless, TNFRSF1A also participates in other pro- or anti-inflammatory pathways in liver cells. The KEGG database showed that TNFRSF1A involves in the mTOR and MAPK pathways to further regulate inflammatory responses, as well as caspase 3 and NFκB pathways to control cell apoptosis, which maybe the inner mechanism of TNFRSF1A regulating liver immune defense and immunity adjustment. Our study indicated that not only the TNFRSF1A membrane protein in septic liver cells significantly decreased but also its gene expression had a specific decline. Its gene regulation mechanism remains to
be investigated. Only by further exploring the duration, concentration, and related inflammatory factors of TNFRSF1A in the immunoregulation of sepsis, can we better understand its role in the occurrence and development of septic liver injury and provide potential insights and targets for the diagnosis and treatment.

In conclusion, our study showed that TNFRSF1A is closely associated with sepsis-induced liver injury, which provides a potential diagnostic signature for septic liver injury and a basis for exploring the roles the liver plays in defense homeostasis during sepsis. TNFRSF1A may serve as an intervention target to alleviate and treat sepsis in the future.

Data Availability
The raw data supporting the conclusions of this article are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
SZ and WZ collected and analyzed the online data. SZ, JL, YH, QW, and YX performed the experiments and prepared the figures. YJ, YW, and WY designed the study and supervised the project. SZ and CD wrote the manuscript. All authors read and approved the final manuscript. Shangxun Zhou and Wei Zhao have contributed equally to this work.

Acknowledgments
This project is supported by the National Natural Science Foundation of China (No. 81871587) and the Natural Science Foundation of Shaanxi Province (No. 2021SF-081).

Supplementary Materials
The abbreviations have been provided in Supplementary Table 1. The online version contains supplementary material available at the website of Genetics Research. (Supplementary Materials)

References
[1] X. Zhang, X. Han, K. Xia et al., “Circulating heparin oligosaccharides rapidly target the hippocampus in sepsis, potentially impacting cognitive functions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 19, pp. 9208–9213, 2019.
[2] H. F. Wang, Y. Li, Y. Q. Wang, H. J. Li, and L. Dou, “MicroRNA-494-3p alleviates inflammatory response in sepsis by targeting TLR6,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 7, pp. 2971–2977, 2019.
[3] Y. Sungkar, J. Considine, and A. Hutchinson, “Implementation of guidelines for sepsis management in emergency departments: a systematic review,” Australasian Emergency Care, vol. 21, no. 4, pp. 111–120, 2018.
[4] Z. Zhang, L. Chen, P. Xu, L. Xing, Y. Hong, and P. Chen, “Gene correlation network analysis to identify regulatory factors in sepsis,” Journal of Translational Medicine, vol. 18, no. 1, p. 381, 2020.
[5] A. Sutherland, M. Thomas, R. A. Brandon et al., “Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis,” Critical Care, vol. 15, no. 3, p. R149, 2011.
[6] Z. G. Shen, J. L. Guo, and D. S. Li, “Screening of differentially expressed genes related to severe sepsis induced by multiple trauma with DNA microarray,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 5, pp. 734–739, 2014.
[7] S. Ahmad, M. M. Ahmed, P. M. Z. Hasan et al., “Identification and validation of potential mirnas, as biomarkers for sepsis and associated lung injury: a network-based approach,” Genes, vol. 11, 2020.
[8] X. Zheng, K. S. Leung, M. H. Wong, and L. Cheng, “Long non-coding RNA pairs to assist in diagnosing sepsis,” BMC Genomics, vol. 22, no. 1, p. 275, 2021.
[9] K. S. Kim, D. W. Jekarl, J. Yoo, S. Lee, M. Kim, and Y. Kim, “Immune gene expression networks in sepsis: a network biology approach,” PLoS One, vol. 16, no. 3, Article ID e0247669, 2021.
[10] Q. Fang, Q. Wang, Z. Zhou, and A. Xie, “Consensus analysis via weighted gene co-expression network analysis (WGCNA) reveals genes participating in early phase of acute respiratory distress syndrome (ARDS) induced by sepsis,” Bioengineering, vol. 12, no. 1, pp. 1161–1172, 2021.
[11] N. Xu, H. Guo, X. Li, Q. Zhao, and J. Li, “A five-genes based diagnostic signature for sepsis-induced ARDS,” Pathology and Oncology Research, vol. 27, Article ID 580801, 2021.
[12] Y. Tang, X. Yang, H. Shu et al., "Bioinformatic analysis identifies potential biomarkers and therapeutic targets of septic-shock-associated acute kidney injury," Hereditas, vol. 158, no. 1, p. 13, 2021.
[13] Y. Wang, X. Yin, and F. Yang, “Comprehensive analysis of gene expression profiles of sepsis-induced multiorgan failure identified its valuable biomarkers,” DNA and Cell Biology, vol. 37, no. 2, pp. 90–98, 2018.
[14] J. Sun, J. Zhang, X. Wang et al., “Gut-liver crosstalk in sepsis-induced liver injury,” Critical Care, vol. 24, no. 1, p. 614, 2020.
[15] P. Strnad, F. Tacke, A. Koch, and C. Trautwein, “Liver—guardian, modifier and target of sepsis,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 1, pp. 55–66, 2017.
[16] Q. Fu, W. Yu, S. Fu, E. Chen, S. Zhang, and T. B. Liang, “Screening and identification of key gene in sepsis development: evidence from bioinformatics analysis,” Medicine (Baltimore), vol. 99, no. 27, Article ID e20759, 2020.
[17] D. W. Jekarl, K. S. Kim, S. Lee, M. Kim, and Y. Kim, “Cytokine and molecular networks in sepsis cases: a network biology approach,” European Cytokine Network, vol. 29, no. 3, pp. 103–111, 2018.
[18] T. Barrett, S. E. Willhite, P. Ledoux et al., “NCBI GEO: archive for functional genomics data sets-update,” Nucleic Acids Research, vol. 41, pp. D991–D995, 2012.
[19] C. Gu, W. Qiao, L. Wang, M. Li, and K. Song, “Identification of genes and pathways associated with multiple organ dysfunction syndrome by microarray analysis,” Molecular Medicine Reports, vol. 18, no. 1, pp. 31–40, 2018.
[20] S. Lambeck, M. Weber, F. A. Gonnert, R. Mrowka, and M. Bauer, "Comparison of sepsis-induced transcriptomic changes in a murine model to clinical blood samples identifies
common response patterns," *Frontiers in Microbiology*, vol. 3, p. 284, 2012.

[21] S. M. Kim, J. R. DeFazio, S. K. Hyoju et al., "Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity," *Nature Communications*, vol. 11, no. 1, p. 2354, 2020.

[22] D. Szklarczyk, A. L. Gable, K. C. Nastou et al., "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets," *Nucleic Acids Research*, vol. 49, no. D1, pp. D605–D612, 2021.

[23] G. Dennis, B. T. Sherman, D. A. Hosack et al., "DAVID: database for annotation, visualization, and integrated discovery," *Genome Biology*, vol. 4, no. 9, p. R60, 2003.

[24] D. Rittirsch, M. S. Huber-Lang, M. A. Flierl, and P. A. Ward, "Immunodesign of experimental sepsis by cecal ligation and puncture," *Nature Protocols*, vol. 4, no. 1, pp. 31–36, 2009.

[25] M. Huang, S. Cai, and J. Su, "The pathogenesis of sepsis and potential therapeutic targets," *International Journal of Molecular Sciences*, vol. 20, no. 21, p. 5376, 2019.

[26] L. Chen, Q. Lu, F. Deng et al., "miR-103a-3p could attenuate sepsis-induced liver injury by targeting HMGB1," *Inflammation*, vol. 43, no. 6, pp. 2075–2086, 2020.

[27] Y. Song, S. Miao, Y. Li, and H. Fu, "Ulinastatin attenuates liver injury and inflammation in a cecal ligation and puncture induced sepsis mouse model," *Journal of Cellular Biochemistry*, vol. 120, no. 1, pp. 417–424, 2019.

[28] J. Yan, S. Li, and S. Li, "The role of the liver in sepsis," *International Reviews of Immunology*, vol. 33, no. 6, pp. 498–510, 2014.

[29] F. C. Gong, R. Ji, Y. M. Wang et al., "Identification of potential biomarkers and immune features of sepsis using bioinformatics analysis," *Mediators of Inflammation*, vol. 2020, Article ID 3432587, 12 pages, 2020.

[30] A. Borghi, L. Verstrepen, and R. Beyaert, "TRAF2 multi-tasking in TNF receptor-induced signaling to NF-κB, MAP kinases and cell death," *Biochemical Pharmacology*, vol. 116, pp. 1-10, 2016.

[31] I. Martinez-Reza, L. Diaz, and R. Garcia-Becerra, "Preclinical and clinical aspects of TNF-alpha and its receptors TNFR1 and TNFR2 in breast cancer," *Journal of Biomedical Science*, vol. 24, no. 1, p. 90, 2017.

[32] Y. Dondelinger, M. Darding, M. J. M. Bertrand, and H. Walczak, "Poly-ubiquitination in TNFR1-mediated necroptosis," *Cellular and Molecular Life Sciences*, vol. 73, pp. 2165–2176, 2016.

[33] M. M. Speeckaert, R. Speeckaert, M. Laute, R. Vanholder, and J. R. Delange, "Tumor necrosis factor receptors: biology and therapeutic potential in kidney diseases," *American Journal of Nephrology*, vol. 36, no. 3, pp. 261–270, 2012.

[34] J. Galon, I. AkSENTijevICH, M. F. McDermott, J. J. O’Shea, and D. L. Kastner, "TNFRSF1A mutations and autoinflammatory syndromes," *Current Opinion in Immunology*, vol. 12, no. 4, pp. 479–486, 2000.